SCHEMBL812635

SCHEMBL812635

CCCOc1ccccc1C=O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.77
HPGD P15428 1/20 0.77
HTT P42858 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
PTGDR2 Q9Y5Y4 1/20 0.58
MAPT P10636 1/20 0.51
KMT2A Q03164 6/20 0.50
LMNA P02545 3/20 0.50
GAA P10253 2/20 0.50
MEN1 O00255 4/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAD52 P43351 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
SRC P12931 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
THRB P10828 1/20 0.46
BLM P54132 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30920025 1.00 ALDH1A1 (0.77) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL21331792 0.94 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL195416 0.90 ALDH1A1 (0.74) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL4947216 0.89 ALDH1A1 (0.71) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL6914412 0.87 ALDH1A1 (1.00) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL29923063 0.87 ALDH1A1 (0.58) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL5724553 0.87 ALDH1A1 (0.58) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL3432906 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL7830929 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL1509367 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108997149-A A kind of dehydroabietylamine derivatives and its preparation method and application that aryl replaces 嘉兴学院 2018-12-14 CN claimed
CN-107245250-A A kind of method for synthesizing disperse red CNB 江苏道博化工有限公司 2017-10-13 CN claimed
EP-2663569-A1 PROCESS FOR PREPARING ALDITOL ACETALS Reliance Industries Limited (IN) 2013-11-20 EP claimed
WO-2012095856-A1 PROCESS FOR PREPARING ALDITOL ACETALS RELIANCE INDUSTRIES LTD. (IN) 2012-07-19 WO claimed
JP-4587669-B2 2010-11-24 JP claimed
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 US claimed
JP-2005509662-A 2005-04-14 JP claimed
EP-1443915-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES Cutanix Corporation (US) 2004-08-11 EP claimed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 US claimed
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments ALLERGAN, INC. 2003-07-03 US claimed
WO-2003043621-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES CUTANIX CORPORATION (US) 2003-05-30 WO claimed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 WO claimed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP claimed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO claimed
US-4582903-A Synthesis of unsaturated hydantoins with an inexpensive catalyst STAUFFER CHEMICAL COMPANY (US) 1986-04-15 US claimed
US-4345072-A Process for the production of 5-arylidene hydantoins (B) DEGUSSA AG (DE) 1982-08-17 US claimed
JP-2256639-A None JP disclosed
EP-4737508-A1 CHEMICAL RECYCLING METHOD FOR MIXED WASTE POLYMERS Korea Research Institute of Chemical Technology (KR) 2026-05-06 EP disclosed
US-4254035-A BY REACTING GLYCINE AND AN AROMATIC ALDEHYDE IN THE PRESENCE OF ACETIC ANHYDRIDE DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1981-03-03 US disclosed
US-4174351-A Separation of dissimilar amines UOP INC. (US) 1979-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments TYR, ALDH2, AOX1 ALDH1A1 4/4885HPGD 286/4885HTT 775/4885
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors MMP9, MMP1, MMP3 ALDH1A1 543/4885HPGD 107/4885HTT 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.